Advancing research into pulmonary fibrosis through innovative clinical trials, Vitti Long Haul explores mesenchymal stem cells therapy, which focuses on reducing lung inflammation, supporting tissue regeneration, and slowing disease progression. This science-driven approach investigates how stem cells and their bioactive factors may help repair damaged lung tissue and improve outcomes for patients with fibrotic lung conditions.
Vitti Long Haul conducts long haul covid clinical trials to evaluate stem cell and exosome-based therapies designed to repair lung tissue, reduce inflammation, and improve respiratory health. Their innovative VL-PX10 and VL-P22 formulations are progressing through advanced clinical stages, offering promising results for patients with lingering post-COVID complications.
New opportunities in regenerative medicine are emerging through clinical trials with mesenchymal stem cells. Vitti Long Haul is conducting Phase 2 studies to evaluate MSC therapies for long COVID and pulmonary fibrosis, aiming to repair lung tissue, reduce inflammation, and restore function. Explore how stem cell research is shaping the future of healing and recovery.
Long COVID affects millions worldwide, bringing lasting challenges like fatigue, brain fog, breathlessness, joint pain, and anxiety that can persist for months or even years. With no officially approved treatments, clinical trials play a crucial role in uncovering solutions and offering patients hope. Learn how this condition impacts daily life, why ongoing research matters, and the importance of finding Hope for Long COVID with Clinical Trials.
Discover the science behind Mesenchymal Stem Cells Therapy, which forms the basis of VL-PX10 and VL-P22—innovative treatments designed for Pulmonary Fibrosis in patients suffering from Long COVID. These therapies utilize exosomes derived from human umbilical cord mesenchymal stem cells (MSCs) to promote tissue repair and immune regulation. Uncover the future of regenerative medicine.
Clinical trials play a vital role in uncovering the causes, symptoms, and potential treatments for Long COVID. At Vitti Long Haul, we believe in the power of research to drive progress. Understanding Long COVID Through Clinical Trials is at the heart of our mission as we lead efforts to study this complex condition. A Phase 2 clinical trial is currently underway in the U.S. for a therapy targeting Pulmonary Fibrosis in patients with Long COVID. Participant recruitment is open — join us in advancing science and supporting those affected by Long COVID.
At Vitti Labs, we have developed VL-PX10 and VL-P22—an innovative therapy utilizing umbilical cord mesenchymal stem cell exosomes, stem cells, and natural biomaterials. This first-of-its-kind combination targets lung scarring in long-haul COVID-19 patients. We are proud to support healing and recovery with advanced regenerative science.
Mesenchymal stem cells are special cells that help heal damaged tissues and reduce harmful inflammation in the body. In the middle of this breakthrough approach, mesenchymal stem cells therapy is showing promise for treating Long Covid symptoms, including lung damage from pulmonary fibrosis. At Vitti Long Haul, you can learn about this therapy, the conditions it treats, and how it may help with long-term illness recovery. Joining a clinical trial could offer new hope and healing.